Question 1

What are the potential benefits of combining relatlimab with nivolumab compared to nivolumab alone?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma clinical trial (NCT03470922). Contact the study team or your healthcare provider for specific answers.

Question 2

How will my eligibility for this trial be determined?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma clinical trial (NCT03470922). Contact the study team or your healthcare provider for specific answers.

Question 3

What side effects should I expect from these treatments?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma clinical trial (NCT03470922). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to come in for treatment and monitoring?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma clinical trial (NCT03470922). Contact the study team or your healthcare provider for specific answers.

Question 5

What happens if I experience side effects during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma clinical trial (NCT03470922). Contact the study team or your healthcare provider for specific answers.

Question 6

Are there other treatment options available that I should consider?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma clinical trial (NCT03470922). Contact the study team or your healthcare provider for specific answers.

What this study is about